leisure time -WSS

leisure time

author：fashion 2025-10-01 07:42:15 - browse：3174

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Search called off for baby washed away in Pennsylvania flash flood

leisure time

hotspot

WSS

CDC Director Mandy Cohen on transparency, trust, and health

CVS is willing to dump 10% of its Medicare Advantage members

The United States must get value

The battle over 'scope creep' and who gets to be called 'doctor'

As H5N1 spreads in cows, experts warn against drinking raw milk

Boston hospital trains restaurant workers on naloxone for overdoses

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Roche’s Alnylam deal shows drug firms interested in heart drugs

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Roche’s Alnylam deal shows drug firms interested in heart drugs

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT series 'Denied by AI' wins major journalism prizes

BioMarin wins approval for gene therapy to treat hemophilia A

The United States must get value

Medicare proposal to cover medical devices draws a mixed reaction

ALS treatment from Biogen, Ionis fails in study

entertainment

Fertility clinic egg and embryo storage is a disaster

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

The battle over 'scope creep' and who gets to be called 'doctor'

WuXi Biologics beefs up its lobbying operation

CVS is willing to dump 10% of its Medicare Advantage members

leisure time

entertainment

hotspot

hotspot